Is atherosclerosis an autoimmune disease?

BMC Medicine

Volumn 12, Issue 1, 2014, Pages

  Matsuura, Eiji ^a   Atzeni, Fabiola ^b   Sarzi Puttini, Piercarlo ^b   Turiel, Maurizio ^c   Lopez, Luis R ^d   Nurmohamed, Michael T ^e  

^a OKAYAMA UNIVERSITY   (Japan)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d Division of Medicine   (United States)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Atherosclerosis; Auto inflammatory disease; Autoimmunity; Inflammasome; Innate immunity; Oxidized LDL; 2 glycoprotein I

Indexed keywords

BETA2 GLYCOPROTEIN 1; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 18; LIPID; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CYTOKINE PRODUCTION; ENDOTHELIAL DYSFUNCTION; HUMAN; IMMUNE DYSREGULATION; INNATE IMMUNITY; LIPID PEROXIDATION; NOTE;

ADAPTIVE IMMUNITY; ANIMALS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; IMMUNITY, INNATE;

EID: 84899155273     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-12-47     Document Type: Note

References (36)

1. Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N, Jara LJ, Abu-Shakra M, Meroni PL, Sherer Y. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005, 112:3337-3347. 10.1161/CIRCULATIONAHA.104.507996, 16301360.
2. Hollan I, Meroni PL, Ahearn JM, Cohen Tervaert JW, Curran S, Goodyear CS, Hestad KA, Kahaleh B, Riggio M, Shields K, Wasko MC. Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev 2013, 12:1004-1015. 10.1016/j.autrev.2013.03.013, 23541482.
3. Nussinovitch U, Shoenfeld Y. Atherosclerosis and macrovascular involvement in systemic sclerosis: myth or reality. Autoimmun Rev 2011, 10:259-266. 10.1016/j.autrev.2010.09.014, 20863903.
4. Artenjak A, Lakota K, Frank M, Čučnik S, Rozman B, Božič B, Shoenfeld Y, Sodin-Semrl S. Antiphospholipid antibodies as non-traditional risk factors in atherosclerosis based cardiovascular diseases without overt autoimmunity, A critical updated review. Autoimmun Rev 2012, 11:873-882. 10.1016/j.autrev.2012.03.002, 22440398.
5. Matsuura E, Lopez LR, Shoenfeld Y, Ames PR. β2-glycoprotein I and oxidative inflammation in early atherogenesis: a progression from innate to adaptive immunity?. Autoimmun Rev 2012, 12:241-249. 10.1016/j.autrev.2012.04.003, 22569463.
6. Sitia S, Tomasoni L, Atzeni F, Ambrosio G, Cordiano C, Catapano A, Tramontana S, Perticone F, Naccarato P, Camici P, Picano E, Cortigiani L, Bevilacqua M, Milazzo L, Cusi D, Barlassina C, Sarzi-Puttini P, Turiel M. From endothelial dysfunction to atherosclerosis. Autoimmun Rev 2010, 9:830-834. 10.1016/j.autrev.2010.07.016, 20678595.
7. Sarzi-Puttini P, Atzeni F, Gerli R, Bartoloni E, Doria A, Barskova T, Matucci-Cerinic M, Sitia S, Tomasoni L, Turiel M. Cardiac involvement in systemic rheumatic diseases: an update. Autoimmun Rev 2010, 9:849-852. 10.1016/j.autrev.2010.08.002, 20692379.
8. Hahn BH, Grossman J, Chen W, McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimm 2007, 28:69-75.
9. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol 2009, 27:165-197. 10.1146/annurev.immunol.021908.132620, 2734407, 19302038.
10. Yin Y, Pastrana JL, Li X, Huang X, Mallilankaraman K, Choi ET, Madesh M, Wang H, Yang XF. Inflammasomes: sensors of metabolic stresses for vascular inflammation. Front Biosci (Landmark Ed) 2013, 18:638-649.
11. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011, 117:3720-3732. 10.1182/blood-2010-07-273417, 3083294, 21304099.
12. Vohnout B, Di Castelnuovo A, Trotta R, D'Orazi A, Panniteri G, Montali A, Donati MB, Arca M, Iacoviello L. Interleukin-1 gene cluster polymorphisms and risk of coronary artery disease. Haematologica 2003, 88:54-60.
13. Sollberger G, Strittmatter GE, Garstkiewicz M, Sand J, Beer HD. Caspase-1: the inflammasome and beyond. Innate Immun 2013, 20:115-125.
14. Petrilli V, Papin S, Dostert C, Mayor A, Martinon F, Tschopp J. Activation of the NARP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ 2007, 14:1583-1589. 10.1038/sj.cdd.4402195, 17599094.
15. Schoneveld AH, Hoefer I, Sluijter JP, Laman JD, de Kleijn DP, Pasterkamp G. Atherosclerotic lesion development and toll like receptor 2 and 4 responsiveness. Atherosclerosis 2008, 197:95-104. 10.1016/j.atherosclerosis.2007.08.004, 17888930.
16. Peters MJ, van Halm VP, Nurmohamed MT, Damoiseaux J, Tervaert JW, Twisk JW, Dijkmans BA, Voskuyl AE. Relations between autoantibodies against oxidized low-density lipoprotein, inflammation, subclinical atherosclerosis, and cardiovascular disease in rheumatoid arthritis. J Rheumatol 2008, 35:1495-1499.
17. Matsuura E, Hughes GRV, Khamashta MA. Oxidation of LDL and its clinical implication. Autoimmun Rev 2008, 7:558-566. 10.1016/j.autrev.2008.04.018, 18625445.
18. Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T. Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997, 107:569-573. 10.1046/j.1365-2249.1997.d01-948.x, 9067534.
19. De Groot PG, Meijers JCM. β2-glycoprotein I: evolution, structure and function. J Thomb Haemost 2011, 9:1275-1284.
20. Kobayashi K, Matsuura E, Liu Q, Furukawa J, Kaihara K, Inagaki J, Atsumi T, Sakairi N, Yasuda T, Voelker DR, Koike T. A specific ligand for β2-glycoprotein I mediates autoantibody-dependent uptake of oxidized low-density lipoprotein by macrophages. J Lipid Res 2001, 42:697-709.
21. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801. 10.1016/j.cell.2006.02.015, 16497588.
22. Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K, Speert D, Fernandes-Alnemri T, Wu J, Monks BG, Fitzgerald KA, Hornung V, Latz E. NF-kB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol 2009, 183:787-791. 10.4049/jimmunol.0901363, 2824855, 19570822.
23. Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host responses. Nature 2006, 442:39-44. 10.1038/nature04946, 16823444.
24. Stutz A, Golenbock DT, Latz E. Inflammasomes: too big to miss. J Clin Invest 2009, 119:3502-3511. 10.1172/JCI40599, 2786809, 19955661.
25. Miller YI, Choi SH, Wiesner P, Fang L, Harkewicz R, Hartvigsen K, Boullier A, Gonen A, Diehl CJ, Que X, Montano E, Shaw PX, Tsimikas S, Binder CJ, Witztum JL. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res 2011, 108:235-248. 10.1161/CIRCRESAHA.110.223875, 3075542, 21252151.
26. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473:317-325. 10.1038/nature10146, 21593864.
27. Reardon CA, Blachowicz L, White T, Cabana V, Wang Y, Lukens J, Bluestone J, Getz GS. Effect of immune deficiency on lipoproteins and atherosclerosis in male apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2001, 21:1011-1016. 10.1161/01.ATV.21.6.1011, 11397712.
28. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006, 86:515-581. 10.1152/physrev.00024.2005, 16601268.
29. Cheng X, Yu X, Ding YJ, Fu QQ, Xie JJ, Tang TT, Yao R, Chen Y, Liao YH. TheTh17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol 2008, 127:89-97. 10.1016/j.clim.2008.01.009, 18294918.
30. George J, Schwartzenberg S, Medvedovsky D, Jonas M, Charach G, Afek A, Shamiss A. Regulatory T cells and IL-10 levels are reduced in patients with vulnerable coronary plaques. Atherosclerosis 2012, 222:519-523. 10.1016/j.atherosclerosis.2012.03.016, 22575708.
31. Gerli R, Schillaci G, Giordano A, Bocci EB, Bistoni O, Vaudo G, Marchesi S, Pirro M, Ragni F, Shoenfeld Y, Mannarino E. CD4 + CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 2004, 109:2744-2748. 10.1161/01.CIR.0000131450.66017.B3, 15159291.
32. Vaudo G, Marchesi S, Gerli R, Allegrucci R, Giordano A, Siepi D, Pirro M, Shoenfeld Y, Schillaci G, Mannarino E. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 2004, 63:31-35. 10.1136/ard.2003.007740, 1754717, 14672888.
33. Liang KP, Kremers HM, Crowson CS, Snyder MR, Therneau TM, Roger VL, Gabriel SE. Autoantibodies and the risk of cardiovascular events. J Rheumatol 2009, 36:2462-2469. 10.3899/jrheum.090188, 2837072, 19833748.
34. Pertovaara M, Kähönen M, Juonala M, Laitinen T, Taittonen L, Lehtimäki T, Viikari JS, Raitakari OT, Hurme M. Autoimmunity and atherosclerosis: the presence of antinuclear antibodies is associated with decreased carotid elasticity in young women. The Cardiovascular Risk in Young Finns Study. Rheumatology (Oxford) 2009, 48:1553-1556.
35. Huang Q, Pope RM. Toll-like receptor signaling: a potential link among rheumatoid arthritis, systemic lupus, and atherosclerosis. J Leukoc Biol 2010, 88:253-262. 10.1189/jlb.0310126, 2908942, 20484668.
36. Bartoloni E, Shoenfeld Y, Gerli R. Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: two faces of the same coin. Arthritis Care Res (Hoboken) 2011, 63:178-183.